Ionis Pharmaceuticals, Inc. Contract with Customer, Liability, Noncurrent
Ionis Pharmaceuticals, Inc. (IONS) had Contract with Customer, Liability, Noncurrent of $63.03 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-07-29
- 2026-06-30: Contract with Customer, Liability, Noncurrent $63.03M.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $75.75M.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $92.00M.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $107.91M.
| Period end | Contract with Customer, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $63.03M 10-Q · filed 2026-07-29 |
| 2026-03-31 | $75.75M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $92.00M 10-Q · filed 2026-07-29 |
| 2025-09-30 | $107.91M 10-Q · filed 2025-10-29 |
| 2025-06-30 | $125.09M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $140.68M 10-Q · filed 2025-04-30 |
| 2024-12-31 | $156.50M 10-K · filed 2026-02-26 |
| 2024-09-30 | $173.78M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $188.70M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $215.09M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $241.18M 10-K · filed 2025-02-19 |
| 2023-09-30 | $249.27M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $254.40M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $272.97M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $287.77M 10-K · filed 2024-02-21 |
| 2022-09-30 | $294.66M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $315.20M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $333.14M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $351.88M 10-K · filed 2023-02-22 |
| 2021-09-30 | $362.89M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $379.87M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $401.97M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $424.05M 10-K · filed 2022-02-25 |
| 2020-09-30 | $429.93M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $448.58M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $467.84M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $490.06M 10-K · filed 2021-02-24 |
| 2019-09-30 | $492.98M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $516.58M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $542.42M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $567.36M 10-K · filed 2020-03-02 |
| 2018-09-30 | $523.38M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $556.59M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $85.45M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $108.03M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |